PL2094849T3 - Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących - Google Patents
Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulującychInfo
- Publication number
- PL2094849T3 PL2094849T3 PL07871436T PL07871436T PL2094849T3 PL 2094849 T3 PL2094849 T3 PL 2094849T3 PL 07871436 T PL07871436 T PL 07871436T PL 07871436 T PL07871436 T PL 07871436T PL 2094849 T3 PL2094849 T3 PL 2094849T3
- Authority
- PL
- Poland
- Prior art keywords
- long term
- immunostimulatory oligonucleotides
- term disease
- disease modification
- modification
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86508906P | 2006-11-09 | 2006-11-09 | |
| PCT/US2007/084358 WO2008073661A2 (en) | 2006-11-09 | 2007-11-09 | Long term disease modification using immunostimulatory oligonucleotides |
| EP07871436.7A EP2094849B1 (en) | 2006-11-09 | 2007-11-09 | Long term disease modification using immunostimulatory oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2094849T3 true PL2094849T3 (pl) | 2014-06-30 |
Family
ID=39512389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07871436T PL2094849T3 (pl) | 2006-11-09 | 2007-11-09 | Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8252757B2 (pl) |
| EP (1) | EP2094849B1 (pl) |
| JP (2) | JP5714818B2 (pl) |
| CN (2) | CN101636495A (pl) |
| AU (1) | AU2007333368C1 (pl) |
| CA (1) | CA2669137A1 (pl) |
| DK (1) | DK2094849T3 (pl) |
| ES (1) | ES2454175T3 (pl) |
| PL (1) | PL2094849T3 (pl) |
| WO (1) | WO2008073661A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1404873B1 (en) * | 2001-06-21 | 2013-05-22 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
| EP1551376A4 (en) * | 2002-08-12 | 2010-10-06 | Dynavax Tech Corp | IMMUNOMODULATORY COMPOSITIONS, PREPARATION METHOD AND USER METHOD THEREFOR |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| ATE544772T1 (de) * | 2002-12-23 | 2012-02-15 | Dynavax Tech Corp | Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür |
| CA2669137A1 (en) | 2006-11-09 | 2008-06-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
| US8815817B2 (en) | 2008-05-15 | 2014-08-26 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
| WO2010067262A1 (en) * | 2008-12-09 | 2010-06-17 | Pfizer Inc. | Immunostimulatory oligonucleotides |
| DE102009034779A1 (de) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen |
| GEP20156313B (en) | 2010-09-22 | 2015-07-10 | Alios Biopharma Inc | Substituted nucleotide analogs |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG |
| WO2018147265A1 (ja) * | 2017-02-07 | 2018-08-16 | 京都府公立大学法人 | 病原性グラム陰性菌に対するワクチン |
| CN113412273B (zh) * | 2019-01-07 | 2025-08-22 | 川斯勒佰尔公司 | 用于治疗原发性纤毛运动障碍的组合物和方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| US5015733A (en) * | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
| US4849513A (en) * | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US5118800A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5118802A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5093232A (en) * | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US4910300A (en) * | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
| US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5460831A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| US5452496A (en) * | 1994-02-03 | 1995-09-26 | Schuller International, Inc. | Vacuum assisted accumulator and process of collecting microfiber |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1996002555A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド／免疫調節分子複合体 |
| WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| DK1009413T3 (da) * | 1997-09-05 | 2007-06-11 | Univ California | Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| AU4343700A (en) | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
| EP1551376A4 (en) * | 2002-08-12 | 2010-10-06 | Dynavax Tech Corp | IMMUNOMODULATORY COMPOSITIONS, PREPARATION METHOD AND USER METHOD THEREFOR |
| ATE544772T1 (de) * | 2002-12-23 | 2012-02-15 | Dynavax Tech Corp | Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür |
| SG160336A1 (en) | 2005-03-04 | 2010-04-29 | Dynavax Tech Corp | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
| CA2669137A1 (en) | 2006-11-09 | 2008-06-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
-
2007
- 2007-11-09 CA CA002669137A patent/CA2669137A1/en not_active Abandoned
- 2007-11-09 PL PL07871436T patent/PL2094849T3/pl unknown
- 2007-11-09 DK DK07871436.7T patent/DK2094849T3/en active
- 2007-11-09 WO PCT/US2007/084358 patent/WO2008073661A2/en not_active Ceased
- 2007-11-09 JP JP2009536527A patent/JP5714818B2/ja not_active Expired - Fee Related
- 2007-11-09 US US11/938,192 patent/US8252757B2/en not_active Expired - Fee Related
- 2007-11-09 ES ES07871436.7T patent/ES2454175T3/es active Active
- 2007-11-09 CN CN200780049562A patent/CN101636495A/zh active Pending
- 2007-11-09 CN CN201510106630.1A patent/CN104857512A/zh active Pending
- 2007-11-09 EP EP07871436.7A patent/EP2094849B1/en not_active Not-in-force
- 2007-11-09 AU AU2007333368A patent/AU2007333368C1/en not_active Ceased
-
2014
- 2014-10-03 JP JP2014204775A patent/JP6023142B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090068208A1 (en) | 2009-03-12 |
| WO2008073661A3 (en) | 2009-02-12 |
| EP2094849A2 (en) | 2009-09-02 |
| JP2010509371A (ja) | 2010-03-25 |
| AU2007333368B2 (en) | 2013-07-18 |
| CN104857512A (zh) | 2015-08-26 |
| CN101636495A (zh) | 2010-01-27 |
| JP6023142B2 (ja) | 2016-11-09 |
| DK2094849T3 (en) | 2014-03-24 |
| EP2094849B1 (en) | 2014-01-08 |
| JP5714818B2 (ja) | 2015-05-07 |
| JP2015028066A (ja) | 2015-02-12 |
| WO2008073661A2 (en) | 2008-06-19 |
| CA2669137A1 (en) | 2008-06-19 |
| US8252757B2 (en) | 2012-08-28 |
| ES2454175T3 (es) | 2014-04-09 |
| AU2007333368C1 (en) | 2014-03-13 |
| AU2007333368A1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI370740B (en) | Immunostimulatory oligonucleotides | |
| PL1957647T3 (pl) | Oligorybonukleotydy immunostymulujące | |
| GB0504436D0 (en) | Vaccine | |
| GB0607088D0 (en) | Vaccine | |
| GB0614780D0 (en) | Biological products | |
| ZA200901666B (en) | Fillings | |
| GB0619182D0 (en) | Oligonucleotide arrays | |
| ZA200902155B (en) | IPV-DPT vaccine | |
| GB0514889D0 (en) | Oligonucleotides | |
| EP2113511A4 (en) | DNA VACCINES FOR FISH | |
| ZA200901592B (en) | Vaccine | |
| ZA200804303B (en) | Immunostimulatory oligoribonucleotides | |
| GB0515135D0 (en) | Vaccine | |
| GB0516944D0 (en) | Vaccine | |
| GB0625593D0 (en) | Vaccine | |
| AU3682P (en) | DC101 Dianella caerulea | |
| GB0619821D0 (en) | Vaccine | |
| GB0608962D0 (en) | Vaccine | |
| GB0619822D0 (en) | Vaccine | |
| GB0607087D0 (en) | Vaccine | |
| GB0619820D0 (en) | Vaccine | |
| GB0606256D0 (en) | Anti-atheroma vaccine | |
| GB0619824D0 (en) | Vaccine | |
| GB0620336D0 (en) | Vaccine | |
| GB0620816D0 (en) | vaccine |